# Integrase Inhibitor (MK-0518) Viral Decay

> **NCT00520897** · PHASE2 · COMPLETED · sponsor: **Canadian Immunodeficiency Research Collaborative** · enrollment: 24 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Raltegravir (MK0518)
- **DRUG:** Placebo
- **PROCEDURE:** Leukopheresis
- **PROCEDURE:** Sigmoid Biopsy

## Key facts

- **NCT ID:** NCT00520897
- **Lead sponsor:** Canadian Immunodeficiency Research Collaborative
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-02
- **Final completion:** 2011-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520897, "Integrase Inhibitor (MK-0518) Viral Decay". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00520897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*